EHA2026 Lymphoma Highlights: frontMIND, POLAR-BEAR, HD-MTX for CNS Lymphoma, EPCORE FL-1

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Carla Casulo, a world-renowned clinician and researcher from the University of Rochester, to discuss the latest highlights from the European Hematology Association (EHA) 2026 conference, focusing on lymphoma.Join us as we dived into four pivotal studies:frontMIND: We explored the efficacy of tafasitamab plus lenalidomide with R-CHOP compared to R-CHOP alone in frontline treatment for diffuse large B-cell lymphoma (DLBCL). Discover the implications of improved progression-free survival (PFS) and the associated toxicities.POLAR-BEAR: We discussed the head-to-head comparison of mini–pola-R-CHP versus mini–R-CHOP in frail or elderly patients with DLBCL. What does this mean for the use of polatuzumab in clinical practice?High-Dose Methotrexate for CNS Prophylaxis: Learn about the significant findings that suggest high-dose methotrexate may not improve outcomes in high-risk patients, potentially changing treatment protocols.EPCOR FL1: We covered the approval of epcoritamab in relapsed and refractory follicular lymphoma, highlighting its benefits and the importance of time-limited therapy.Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media:X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/Tune in for an insightful discussion on these important studies and their potential impact on clinical practice. Don't forget to subscribe for more updates on conference highlights, FDA approvals, and treatment algorithms!#Lymphoma, #DLBCL, #EHA2026, #Hematology, #OncologyBrothers